Hindy Joya-Rita, Haddad Sara F, Kanj Souha S
Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Curr Opin Infect Dis. 2022 Apr 1;35(2):112-119. doi: 10.1097/QCO.0000000000000800.
Staphylococcus aureus is a pathogen incriminated in skin and soft tissue infections (SSTIs), with methicillin-resistant S. aureus (MRSA) becoming the predominant cause and representing a significant burden to the healthcare system. The last updated Infectious Diseases Society of America (IDSA) guidelines concerning MRSA infections and SSTIs management were published in 2011 and 2014, respectively. The UK updated guidelines for MRSA infection treatment were published in 2021. Older treatment options may be associated with toxicity and require frequent dosing. There is a paucity of recent reviews on the armamentarium of new agents for MRSA SSTIs treatment.
Since 2005, several new antibiotics received a fast-track approval by the Food and Drug Administration (FDA) for SSTI treatment. These drugs include delafloxacin, omadacycline, tedizolid, ceftaroline, dalbavancin, oritavancin and telavancin. In this manuscript, we will review the data that led to these new drugs approval and discuss their advantages and disadvantages in MRSA SSTIs management.
MRSA is a major cause of SSTIs. Several novel therapies covering MRSA were FDA-approved for SSTIs. However, the current IDSA guidelines for MRSA infection and SSTIs as well as the recently published UK guidelines on MRSA treatment only consider these drugs as alternative choices or do not mention them at all.
金黄色葡萄球菌是皮肤和软组织感染（SSTIs）的致病原，耐甲氧西林金黄色葡萄球菌（MRSA）已成为主要病因，并给医疗系统带来重大负担。美国感染病学会（IDSA）关于MRSA感染和SSTIs管理的最新指南分别于2011年和2014年发布。英国关于MRSA感染治疗的更新指南于2021年发布。较老的治疗方案可能具有毒性，且需要频繁给药。关于治疗MRSA SSTIs的新型药物的现有综述较少。
自2005年以来，几种新型抗生素获得了美国食品药品监督管理局（FDA）的快速批准用于SSTIs治疗。这些药物包括达氟沙星、奥玛环素、替地珠利、头孢洛林、达巴万星、奥利万星和特拉万星。在本手稿中，我们将回顾促使这些新药获批的数据，并讨论它们在MRSA SSTIs管理中的优缺点。
MRSA是SSTIs的主要病因。几种涵盖MRSA的新型疗法已获FDA批准用于SSTIs。然而，当前IDSA关于MRSA感染和SSTIs的指南以及最近发布的英国MRSA治疗指南仅将这些药物视为替代选择或根本未提及它们。
